Krystal Biotech, Inc.
KRYS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 473% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.1% | 93.9% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 22.6% | -216.4% | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 30.7% | 21.6% | – | – |
| EPS | 3.12 | 0.4 | -5.49 | -3.13 |
| % Growth | 680% | 107.3% | -75.4% | – |
| EPS Diluted | 3 | 0.39 | -5.49 | -3.13 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 37.8% | -180.1% | – | – |